Achembio, a Fibrosis Company

With offices in Jeju Korea, Achembio is a bio-tech company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe fibrosis diseases.

Achembio is a leader in hypoxia therapies, with a unique therapeutic approach based on the inhibition of HIF-1α enzymes. The study results validated the efficacy of our lead assets for IPF with potentially less adverse effects in multiple systems using cellular and animal models.

Achembio’s experienced research and development team is rapidly advancing the candidates for the treatment of IPF and other pipeline candidates for IPF and other severe fibrosis diseases.